0001551152-20-000010.txt : 20200501 0001551152-20-000010.hdr.sgml : 20200501 20200501074453 ACCESSION NUMBER: 0001551152-20-000010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200501 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200501 DATE AS OF CHANGE: 20200501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 20838368 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20200331x8k.htm 8-K Document
false0001551152Common Stock, par value $0.01 per shareABBV 0001551152 2020-05-01 2020-05-01 0001551152 exch:XNYS us-gaap:CommonStockMember 2020-05-01 2020-05-01 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2020-05-01 2020-05-01 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2020-05-01 2020-05-01 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2020-05-01 2020-05-01 0001551152 exch:XNYS abbv:Sec1.375SeniorNotesDue2024Member 2020-05-01 2020-05-01 0001551152 exch:XCHI us-gaap:CommonStockMember 2020-05-01 2020-05-01


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________________________________
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 1, 2020
 
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware
 
001-35565
 
32-0375147
(State or other Jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
 
 
 
Identification No.)
 _____________________________________________________
 
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (847) 932-7900
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.01 Par Value
 
ABBV
 
New York Stock Exchange
 
 
 
 
Chicago Stock Exchange
1.375% Senior Notes due 2024
 
ABBV24
 
New York Stock Exchange
0.750% Senior Notes due 2027
 
ABBV27
 
New York Stock Exchange
2.125% Senior Notes due 2028
 
ABBV28
 
New York Stock Exchange
1.250% Senior Notes due 2031
 
ABBV31
 
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐   
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   
 




Item 2.02  Results of Operations and Financial Condition
 
On May 1, 2020, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2020.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits

(d) Exhibits





SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
ABBVIE INC.
 
 
 
 
Date:
May 1, 2020
By:
/s/ Robert A. Michael
 
 
 
Robert A. Michael
 
 
 
Executive Vice President,
 
 
 
Chief Financial Officer

 



 EX-99.1 2 abbv-20200331xexhibit9.htm EXHIBIT 99.1 Exhibit


abbvieimage1a39.jpg
 



PRESS RELEASE
 
AbbVie Reports First-Quarter 2020 Financial Results
 
•
Reports First-Quarter Diluted EPS of $2.02 on a GAAP Basis; Adjusted Diluted EPS of $2.42

•
First-Quarter Net Revenues Were $8.619 Billion, an Increase of 10.1 Percent on a GAAP Basis, or 10.7 Percent Operationally

•
First-Quarter U.S. HUMIRA Net Revenues Were $3.656 Billion, an Increase of 13.7 Percent; Internationally, HUMIRA Net Revenues Were $1.047 Billion, a Decrease of 14.9 Percent on a Reported Basis, or 12.8 Percent Operationally, Due to Biosimilar Competition

•
First-Quarter Global Net Revenues From the Hematologic Oncology Portfolio Were $1.549 Billion, an Increase of 32.1 Percent on a Reported Basis, or 32.3 Percent Operationally; First-Quarter Global IMBRUVICA Net Revenues Were $1.232 Billion, an Increase of 20.6 Percent, with U.S. Net Revenues of $966 Million and International Profit Sharing of $266 Million; Global VENCLEXTA Net Revenues Were $317 Million

•
First-Quarter Global SKYRIZI Net Revenues Were $300 Million; Global RINVOQ Net Revenues Were $86 Million

•
Donates $35 Million for COVID-19 Relief to Support Healthcare Systems, Patients and Communities; Supports COVID-19 Clinical Research by Collaborating with Health Authorities and Institutions Globally

•
AbbVie Announced Final Approval from the European Commission and Entered into a Consent Decree Agreement with Staff of the U.S. Federal Trade Commission Regarding the Pending Allergan Transaction; AbbVie Expects to Close the Pending Allergan Transaction in May 2020

•
Updates Standalone 2020 GAAP Diluted EPS Guidance Range From $7.66 to $7.76 to $7.60 to $7.70, Representing Growth of 44.9 Percent at the Midpoint; Confirms Standalone 2020 Adjusted Diluted EPS Guidance Range of $9.61 to $9.71, Representing Growth of 8.1 Percent at the Midpoint
 
NORTH CHICAGO, Ill., May 1, 2020 – AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2020.
 
"During this challenging time, we are doing everything possible to ensure our employees remain safe, our patients receive their medicines and assistance is available to help those most deeply impacted by the COVID-19 pandemic,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Our business continues to perform well and remains strong, which speaks volumes as to the robustness of our portfolio and the commitment from our many dedicated employees across the organization."


Note: "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year’s foreign exchange rates.    1


First-Quarter Results
 
•
Worldwide net revenues were $8.619 billion, an increase of 10.1 percent on a reported basis, or 10.7 percent operationally, including a 240 basis point stocking benefit related to the COVID-19 pandemic.

•
Global HUMIRA net revenues of $4.703 billion increased 5.8 percent on a reported basis, or 6.4 percent operationally. U.S. HUMIRA net revenues were $3.656 billion, an increase of 13.7 percent. Internationally, HUMIRA net revenues were $1.047 billion, a decrease of 14.9 percent on a reported basis, or 12.8 percent operationally, due to biosimilar competition.

•
Global net revenues from the hematologic oncology portfolio were $1.549 billion, an increase of 32.1 percent on a reported basis, or 32.3 percent operationally. Global IMBRUVICA net revenues were $1.232 billion, an increase of 20.6 percent, with U.S. net revenues of $966 million and international profit sharing of $266 million. Global VENCLEXTA net revenues were $317 million.

•
Global SKYRIZI net revenues were $300 million and global RINVOQ net revenues were $86 million.

•
On a GAAP basis, the gross margin ratio in the first quarter was 77.5 percent. The adjusted gross margin ratio was 82.7 percent.

•
On a GAAP basis, selling, general and administrative expense was 19.7 percent of net revenues. The adjusted SG&A expense was 18.6 percent of net revenues.

•
On a GAAP basis, research and development expense was 16.0 percent of net revenues. The adjusted R&D expense was 14.3 percent of net revenues, reflecting funding actions supporting all stages of our pipeline.

•
On a GAAP basis, the operating margin in the first quarter was 41.8 percent. The adjusted operating margin was 49.8 percent.

•
On a GAAP basis, net interest expense was $428 million. The adjusted net interest expense was $284 million.

•
On a GAAP basis, the tax rate in the quarter was 2.8 percent. The adjusted tax rate was 9.7 percent.

•
Diluted EPS in the first quarter was $2.02 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.42, including a $0.09 stocking benefit related to the COVID-19 pandemic.

Note: "Operational" comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year’s foreign exchange rates.    2


Recent Events

•
AbbVie announced a donation of $35 million to support COVID-19 relief efforts with partners International Medical Corps, Direct Relief and Feeding America. In the U.S., AbbVie's funds will be used to support healthcare capacity for hospitals as well as protect vulnerable populations by enabling access to food and essential supplies. In Europe, the donation will provide critical equipment and supplies to patients and front-line healthcare workers in the hardest-hit countries. Additionally, AbbVie is doubling the AbbVie Foundation match for COVID-19-related contributions by its employees, whereby the AbbVie Foundation will match $2 to every $1 employees donate to a nonprofit for this purpose.

•
AbbVie is supporting COVID-19 clinical research by collaborating with health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of KALETRA/ALUVIA (lopinavir/ritonavir), AbbVie’s antiretroviral therapy for the treatment of HIV, against COVID-19. Collaboration partners include European health authorities and the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority. Along with industry partners, the company has joined the Innovative Medicines Initiative to support research and discovery of targeted medicines against COVID-19.

•
AbbVie has initiated the Phase 2 iNSPIRE clinical trial to evaluate the potential of IMBRUVICA (ibrutinib) to treat patients with moderate to severe COVID-19. The trial will evaluate the role of IMBRUVICA in preventing pro-inflammatory cytokines through multiple pathways and reducing the risk of pulmonary failure, the most common cause of mortality related to COVID-19 infection. The study aims to determine the safety and efficacy of adding IMBRUVICA to best supportive care in treating patients with COVID-19 pulmonary distress.

•
AbbVie announced it received final approval from the European Commission (EC) and has entered into a consent decree agreement with staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie's pending acquisition of Allergan. The consent decree remains subject to further review and approval by the Commissioners of the FTC. AbbVie and Allergan anticipate deal closing in May 2020.

•
AbbVie announced the FDA approval of IMBRUVICA in combination with rituximab for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The approval is based on positive results from the landmark Phase 3 E1912 study, in which IMBRUVICA plus rituximab demonstrated superior progression free survival (PFS) against the chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) for previously untreated patients with CLL. This milestone marks the 11th FDA approval for IMBRUVICA since it was first approved in 2013 and the sixth in CLL. IMBRUVICA is jointly developed and commercialized with Janssen Biotech, Inc.

•
AbbVie announced that the EC has approved VENCLYXTO (venetoclax) in combination with obinutuzumab for the treatment of adult patients with CLL who were previously untreated. VENCLYXTO plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the EC for patients with previously untreated CLL. Approval is based on data from the Phase 3 CLL14 trial, which showed that patients treated with obinutuzumab plus one year of treatment with VENCLYXTO had superior PFS and higher rates of undetectable minimal residual disease compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil. Venetoclax is being developed by AbbVie and Roche and is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.






    3


Recent Events (continued)

•
AbbVie announced results from two Phase 3 studies (VIALE-A and VIALE-C) for VENCLEXTA (venetoclax) in patients with previously-untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. The VIALE-A trial, which evaluated VENCLEXTA in combination with azacitidine versus azacitidine plus placebo, met its dual primary endpoints of overall survival (OS) and composite complete remission rate. The VIALE-A study was stopped early due to positive efficacy results at the first interim analysis for OS. The VIALE-C trial, which evaluated VENCLEXTA in combination with low-dose cytarabine (LDAC) versus LDAC plus placebo, did not demonstrate statistically significant improvement in the primary endpoint of OS, but results were indicative of clinical activity of VENCLEXTA in combination with LDAC. In November 2018, AbbVie received accelerated approval in the U.S. for VENCLEXTA in combination with azacitidine, decitabine, or LDAC for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy based on the Phase 1/2 studies. The results of VIALE-A and VIALE-C will be provided to the FDA and submitted for regulatory approval by other global health authorities later this year.

•
AbbVie announced that the EC has approved a change to the marketing authorization for MAVIRET (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. The decision makes MAVIRET the only pan-genotypic (GTs 1-6) 8-week treatment option for treatment-naïve, chronic HCV patients, without cirrhosis or with compensated cirrhosis. The approval is supported by data from the Phase 3b EXPEDITION-8 study, which showed that with 8 weeks of MAVIRET, an overall 98 percent patients achieved a sustained virologic response 12 weeks after treatment (SVR12), and for patients with GT3, the SVR12 rate was over 95 percent.

Full-Year 2020 Outlook
AbbVie is updating its standalone GAAP diluted EPS guidance for the full-year 2020 from $7.66 to $7.76 to $7.60 to $7.70, representing growth of 44.9 percent at the midpoint. AbbVie is confirming the previous expectation to deliver standalone adjusted diluted EPS for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint. The company’s standalone 2020 adjusted diluted EPS guidance excludes $2.01 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.
Statements Required by the Irish Takeover Rules

The directors of AbbVie accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of AbbVie (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Any holder of 1 percent or more of any class of relevant securities of AbbVie Inc. may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.


    4


Conference Call
 
AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our first-quarter performance. The call will be webcast through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central time.

Non-GAAP Financial Results
 
Financial results for 2020 and 2019 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company’s 2020 financial guidance is also being provided on both a reported and a non-GAAP basis.
Forward-Looking Statements
 
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on AbbVie’s operations, results and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that the proposed acquisition of Allergan will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the proposed acquisition, failure to realize the expected benefits of the proposed acquisition, failure to promptly and effectively integrate Allergan's businesses, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the proposed acquisition, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission (SEC). AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Profit Forecasts
AbbVie is updating its GAAP diluted EPS guidance for the full-year 2020 from $7.66 to $7.76 to $7.60 to $7.70, representing growth of 44.9 percent at the midpoint.
AbbVie is confirming its adjusted diluted EPS guidance for the full-year 2020 of $9.61 to $9.71, representing growth of 8.1 percent at the midpoint.
AbbVie expects adjusted diluted EPS for the second quarter of 2020 of between $2.10 and $2.16, excluding approximately 53 cents of non-cash amortization and other specified items.
The guidance statements above regarding GAAP EPS and adjusted EPS for the full-year 2020 and adjusted EPS for the second quarter of 2020 each constitute a profit forecast for the purposes of the Rule 28 of the Irish Takeover Rules.
The company will issue 2020 combined company guidance following the close of the planned Allergan acquisition.

    5


* Adjusted Earnings Per Share (“EPS”) is a non-GAAP diluted earnings per share, typically reported in AbbVie’s quarterly and annual financial results for the full year, guidance and in the earnings calls for the next quarter guidance updates. This is not prepared in accordance with U.S. GAAP. This non-GAAP financial measure should not be considered in isolation from, as a substitute for, or superior to financial measures prepared in accordance with U.S. GAAP.
Adjusted EPS is calculated as net income excluding certain non-cash items and factors which are unusual or unpredictable, which include: amortization and impairment of intangible assets; change in fair value of contingent consideration; major restructuring costs, integration and other related transaction costs relating to acquisitions; litigation reserves; R&D milestones and acquired IPR&D, together with the tax effects of all these items.
Basis of preparation
The AbbVie profit forecasts (the “Profit Forecasts”) are based on the unaudited interim financial results for the three months ended March 31, 2020 and a forecast of the results for the nine months to December 31, 2020.
In accordance with Rule 28 of the Irish Takeover Rules, the directors of AbbVie confirm that the Profit Forecasts have been properly compiled on the basis of the assumptions stated below on a basis consistent with the accounting policies of AbbVie, which are in accordance with U.S. GAAP and those which AbbVie anticipates will be applicable for the full year ending December 31, 2020 (as adjusted for AbbVie non-GAAP policy to disclose adjusted earnings excluding specified items).
The AbbVie non-GAAP profit forecast does not include the proposed acquisition of Allergan. However, the AbbVie GAAP profit forecast includes estimated one-time expenses relating to the transaction such as financing costs, legal, consultants, accountants, regulatory and other fees, which are expected to be incurred in 2020.
Principal assumptions
The Profit Forecasts have been compiled on the basis of the following assumptions:
Assumptions which are within AbbVie’s influence or control:
•
Executed licensing and partnership collaboration transaction impacts and transactions expected to be executed in the next quarter are included. In line with AbbVie’s historical practices, management continues to evaluate and pursue opportunities for further partnership collaborations and in-licensing transactions. No material acquisitions or disposals are anticipated in 2020;
•
There will be no material change in the operational strategy or current management of AbbVie during the year ending December 31, 2020 other than those already announced;
•
There will be no major site closures or rationalization during the nine-month forecast period to December 31, 2020.
•
Share repurchases and issuances are expected to be relatively flat during the nine-month forecast period to December 31, 2020.
Assumptions which are outside of AbbVie’s influence or control:
•
There will be no material supply chain, manufacturing and distribution disruptions and other business interruptions, including natural disasters or industrial disputes;
•
There will be no material adverse events that affect AbbVie’s key products, including adverse regulatory and clinical findings or publications, product recalls, liability claims, or loss of patent protection;
•
There will be no material changes to current litigation provisions due to a new or ongoing litigation claim;

    6


•
There will be no material change in general market, economic, competitive environments or levels of demand in countries in which AbbVie operates that would materially affect AbbVie’s business;
•
There will be no material change to AbbVie customers’ agreements, rebates, or discount programs from those currently prevailing;
•
With respect to COVID-19 that: “stay at home” orders will be gradually lifted, starting in May, across Europe and the United States; over the subsequent 60 days, physicians' offices and hospitals will reopen for more routine patient diagnosis and care; and patients will start returning to physician offices for routine treatment in that timeframe. An increase to AbbVie's patient assistance programs, as well as a shifts in the U.S. payor mix due to increased unemployment has also been factored in.
•
There will be no changes in exchange rates, interest rates, bases of taxes, tax laws or interpretations, or legislative or regulatory requirements from those currently prevailing that would have a material impact on AbbVie’s operations or its accounting policies;
•
There will be no material change to discount rate assumptions for calculating the fair value of contingent consideration from those currently prevailing; and
•
There will be no intangible asset impairments due to unfavorable clinical study results or safety signals.

 
Media:
Investors:
Adelle Infante
Liz Shea
(847) 938-8745
(847) 935-2211
 
 
 
Todd Bosse
 
(847) 936-1182
 
 
 
Jeffrey Byrne
 
(847) 938-2923

    7


AbbVie Inc.
Key Product Revenues
Quarter Ended March 31, 2020
(Unaudited)
 
 
 
 
 
 
 
 
% Change vs. 1Q19
 
Net Revenues (in millions)
 
 
 
International
Total
 
U.S.
 
Int’l.
 
Total
 
U.S.
 
Operational
 
Reported
Operational
 
Reported
ADJUSTED NET REVENUESa
$6,158
 
$2,461
 
$8,619
 
16.8%
 
(2.0)%
 
(3.8)%
10.7%
 
10.1%
Immunology
4,004
 
1,085
 
5,089
 
24.5
 
(9.7)
 
(11.8)
15.1
 
14.5
Humira
3,656
 
1,047
 
4,703
 
13.7
 
(12.8)
 
(14.9)
6.4
 
5.8
Skyrizi
266
 
34
 
300
 
n/m
 
n/m
 
n/m
n/m
 
n/m
Rinvoq
82
 
4
 
86
 
n/m
 
n/m
 
n/m
n/m
 
n/m
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematologic Oncology
1,167
 
382
 
1,549
 
25.0
 
61.1
 
59.9
32.3
 
32.1
Imbruvicab
966
 
266
 
1,232
 
16.6
 
37.9
 
37.9
20.6
 
20.6
Venclexta
201
 
116
 
317
 
91.5
 
>100.0
 
>100.0
>100.0
 
>100.0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HCV
234
 
330
 
564
 
(41.9)
 
(18.8)
 
(20.0)
(30.2)
 
(30.8)
Mavyret
234
 
325
 
559
 
(42.0)
 
(14.7)
 
(16.0)
(28.6)
 
(29.2)
Viekira
—
 
5
 
5
 
n/m
 
(80.6)
 
(81.2)
(80.3)
 
(80.9)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other Key Products
769
 
543
 
1,312
 
3.9
 
0.2
 
(1.8)
2.4
 
1.5
Creon
276
 
—
 
276
 
21.9
 
n/a
 
n/a
21.9
 
21.9
Lupron
195
 
38
 
233
 
2.1
 
2.1
 
(0.3)
2.1
 
1.7
Synthroid
205
 
—
 
205
 
12.3
 
n/a
 
n/a
12.3
 
12.3
Synagis
—
 
270
 
270
 
n/a
 
(4.1)
 
(5.6)
(4.1)
 
(5.6)
Duodopa
25
 
99
 
124
 
10.2
 
14.9
 
12.0
14.0
 
11.7
Sevoflurane
16
 
63
 
79
 
(6.1)
 
(13.5)
 
(15.8)
(12.2)
 
(14.0)
Kaletra
14
 
72
 
86
 
3.2
 
13.1
 
10.8
11.4
 
9.5
Orilissa
30
 
1
 
31
 
>100.0
 
>100.0
 
>100.0
>100.0
 
>100.0
AndroGel
8
 
—
 
8
 
(89.1)
 
n/a
 
n/a
(89.1)
 
(89.1)
Note: “Operational” comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year’s foreign exchange rates.
n/a = not applicable
n/m = not meaningful
a  
Adjusted net revenues exclude specified items. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Percentage change is calculated using adjusted net revenues.
b  
Reflects profit sharing for Imbruvica international revenues.

    8


AbbVie Inc.
Consolidated Statements of Earnings
Quarter Ended March 31, 2020 and 2019
(Unaudited) (In millions, except per share data)
 
 
First Quarter
Ended March 31
 
2020
 
2019
Net revenues
$
8,619

 
$
7,828

Cost of products sold
1,942

 
1,694

Selling, general and administrative
1,695

 
1,680

Research and development
1,379

 
1,289

Acquired in-process research and development
—

 
155

Total operating costs and expenses
5,016

 
4,818

 
 
 
 
Operating earnings
3,603

 
3,010

 
 
 
 
Interest expense, net
428

 
325

Net foreign exchange loss
5

 
6

Other expense, net
72

 
135

Earnings before income tax expense
3,098

 
2,544

Income tax expense
88

 
88

Net earnings
$
3,010

 
$
2,456

 
 
 
 
Diluted earnings per share
$
2.02

 
$
1.65

 
 
 
 
Adjusted diluted earnings per sharea
$
2.42

 
$
2.14

 
 
 
 
Weighted-average diluted shares outstanding
1,484

 
1,483

 
a 
Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.






    9


AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended March 31, 2020
(Unaudited) (In millions, except per share data)
 1.     Specified items impacted results as follows:
 
1Q20
 
Earnings
 
Diluted
 
Pre-tax
 
After-tax
 
EPS
As reported (GAAP)
$
3,098

 
$
3,010

 
$
2.02

Adjusted for specified items:
 

 
 

 
 

Intangible asset amortization
444

 
371

 
0.24

Acquisition related costs
188

 
158

 
0.11

Milestones and other R&D expenses
135

 
115

 
0.08

Change in fair value of contingent consideration
72

 
72

 
0.05

Other
66

 
(113
)
 
(0.08
)
As adjusted (non-GAAP)
$
4,003

 
$
3,613

 
$
2.42

Acquisition related costs reflect transaction and financing costs related to the proposed Allergan acquisition. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. Other primarily includes the impacts of tax law changes, charitable contributions to support COVID-19 relief efforts and restructuring charges associated with streamlining global operations.
2. The impact of the specified items by line item was as follows: 
 
1Q20
 
Cost of products sold
 
SG&A
 
R&D
 
Interest expense, net
 
Other expense, net
As reported (GAAP)
$
1,942

 
$
1,695

 
$
1,379

 
$
428

 
$
72

Adjusted for specified items:
 
 
 
 
 
 
 
 
 
Intangible asset amortization
(444
)
 
—

 
—

 
—

 
—

Acquisition related costs
—

 
(44
)
 
—

 
(144
)
 
—

Milestones and other R&D expenses
—

 
—

 
(135
)
 
—

 
—

Change in fair value of contingent consideration
—

 
—

 
—

 
—

 
(72
)
Other
(4
)
 
(52
)
 
(10
)
 
—

 
—

As adjusted (non-GAAP)
$
1,494

 
$
1,599

 
$
1,234

 
$
284

 
$
—

3. The adjusted tax rate for the first quarter of 2020 was 9.7 percent, as detailed below:
 
1Q20
 
Pre-tax
earnings
 
Income
taxes
 
Tax rate
As reported (GAAP)
$
3,098

 
$
88

 
2.8
%
Specified items
905

 
302

 
33.4
%
As adjusted (non-GAAP)
$
4,003

 
$
390

 
9.7
%

    10


AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended March 31, 2019
(Unaudited) (In millions, except per share data)
 
1.     Specified items impacted results as follows:
 
1Q19
 
Earnings
 
Diluted
 
Pre-tax
 
After-tax
 
EPS
As reported (GAAP)
$
2,544

 
$
2,456

 
$
1.65

Adjusted for specified items:
 

 
 

 
 

Intangible asset amortization
385

 
318

 
0.21

Milestones and other R&D expenses
40

 
40

 
0.03

Acquired IPR&D
155

 
155

 
0.10

Change in fair value of contingent consideration
169

 
171

 
0.12

Restructuring
163

 
133

 
0.09

Litigation reserves
10

 
8

 
—

Tax audit settlement
—

 
(89
)
 
(0.06
)
As adjusted (non-GAAP)
$
3,466

 
$
3,192

 
$
2.14

Milestones and other R&D expenses are associated with milestone payments for previously announced collaborations. Acquired IPR&D primarily reflects upfront payments related to R&D collaborations and licensing arrangements with third parties. Restructuring is primarily associated with streamlining global operations.
2. The impact of the specified items by line item was as follows: 
 
1Q19
 
Cost of products sold
 
SG&A
 
R&D
 
Acquired
IPR&D
 
Other expense, net
As reported (GAAP)
$
1,694

 
$
1,680

 
$
1,289

 
$
155

 
$
135

Adjusted for specified items:
 
 
 
 
 
 
 
 
 
Intangible asset amortization
(385
)
 
—

 
—

 
—

 
—

Milestones and other R&D expenses
—

 
—

 
(40
)
 
—

 
—

Acquired IPR&D
—

 
—

 
—

 
(155
)
 
—

Change in fair value of contingent consideration
—

 
—

 
—

 
—

 
(169
)
Restructuring
(6
)
 
(107
)
 
(50
)
 
—

 
—

Litigation reserves
—

 
(10
)
 
—

 
—

 
—

As adjusted (non-GAAP)
$
1,303

 
$
1,563

 
$
1,199

 
$
—

 
$
(34
)
 
3. The adjusted tax rate for the first quarter of 2019 was 7.9 percent, as detailed below:
 
1Q19
 
Pre-tax
earnings
 
Income
taxes
 
Tax rate
As reported (GAAP)
$
2,544

 
$
88

 
3.5
%
Specified items
922

 
186

 
20.2
%
As adjusted (non-GAAP)
$
3,466

 
$
274

 
7.9
%

    11
 EX-101.SCH 3 abbv-20200501.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 abbv-20200501_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 abbv-20200501_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 abbv-20200501_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Sec 1.375 Senior Notes Due 2024 [Member] Sec 1.375 Senior Notes Due 2024 [Member] Sec 1.375 Senior Notes Due 2024 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Sec 1.250 Senior Notes due 2031 [Member] Sec 1.250 Senior Notes due 2031 [Member] Sec 1.250 Senior Notes due 2031 [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Exchange [Domain] Exchange [Domain] NEW YORK STOCK EXCHANGE, INC. [Member] NEW YORK STOCK EXCHANGE, INC. [Member] CHICAGO STOCK EXCHANGE, INC [Member] CHICAGO STOCK EXCHANGE, INC [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 7 abbv-20200501_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 abbvieimage1a39.jpg begin 644 abbvieimage1a39.jpg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end XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 7 95 1 false 7 0 false 0 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.abbvie.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports abbv-20200331x8k.htm abbv-20200331xexhibit9.htm abbv-20200501.xsd abbv-20200501_cal.xml abbv-20200501_def.xml abbv-20200501_lab.xml abbv-20200501_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/exch/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 abbv-20200331x8k_htm.xml IDEA: XBRL DOCUMENT 0001551152 2020-05-01 2020-05-01 0001551152 us-gaap:CommonStockMember exch:XNYS 2020-05-01 2020-05-01 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2020-05-01 2020-05-01 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2020-05-01 2020-05-01 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2020-05-01 2020-05-01 0001551152 abbv:Sec1.375SeniorNotesDue2024Member exch:XNYS 2020-05-01 2020-05-01 0001551152 us-gaap:CommonStockMember exch:XCHI 2020-05-01 2020-05-01 false 0001551152 Common Stock, par value $0.01 per share ABBV 8-K 2020-05-01 ABBVIE INC. DE 001-35565 32-0375147 1 North Waukegan Road North Chicago IL 60064-6400 847 932-7900 false false false false Common Stock, $0.01 Par Value ABBV NYSE CHX 1.375% Senior Notes due 2024 ABBV24 NYSE 0.750% Senior Notes due 2027 ABBV27 NYSE 2.125% Senior Notes due 2028 ABBV28 NYSE 1.250% Senior Notes due 2031 ABBV31 NYSE false XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information Document
May 01, 2020
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 01, 2020
Entity Registrant Name ABBVIE INC.
Entity Central Index Key 0001551152
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35565
Entity Tax Identification Number 32-0375147
Entity Address, Address Line One 1 North Waukegan Road
Entity Address, City or Town North Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 847
Local Phone Number 932-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 Par Value
Trading Symbol ABBV
Security Exchange Name NYSE
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol ABBV
Security Exchange Name CHX
Sec 1.375 Senior Notes Due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 1.375% Senior Notes due 2024
Trading Symbol ABBV24
Security Exchange Name NYSE
Sec 0.750 Senior Notes Due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.750% Senior Notes due 2027
Trading Symbol ABBV27
Security Exchange Name NYSE
Sec 2.125 Senior Notes due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 2.125% Senior Notes due 2028
Trading Symbol ABBV28
Security Exchange Name NYSE
Sec 1.250 Senior Notes due 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 1.250% Senior Notes due 2031
Trading Symbol ABBV31
Security Exchange Name NYSE
XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abbv-20200331x8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 7, "dts": { "calculationLink": { "local": [ "abbv-20200501_cal.xml" ] }, "definitionLink": { "local": [ "abbv-20200501_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "abbv-20200331x8k.htm" ] }, "labelLink": { "local": [ "abbv-20200501_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "abbv-20200501_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abbv-20200501.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 36, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 4, "memberStandard": 3, "nsprefix": "abbv", "nsuri": "http://www.abbvie.com/20200501", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "abbv-20200331x8k.htm", "contextRef": "D2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document", "role": "http://www.abbvie.com/role/DocumentAndEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "abbv-20200331x8k.htm", "contextRef": "D2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 7, "tag": { "abbv_Sec0.750SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]", "label": "Sec 0.750 Senior Notes Due 2027 [Member]", "terseLabel": "Sec 0.750 Senior Notes Due 2027 [Member]" } } }, "localname": "Sec0.750SeniorNotesDue2027Member", "nsuri": "http://www.abbvie.com/20200501", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec1.250SeniorNotesdue2031Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 1.250 Senior Notes due 2031 [Member]", "label": "Sec 1.250 Senior Notes due 2031 [Member]", "terseLabel": "Sec 1.250 Senior Notes due 2031 [Member]" } } }, "localname": "Sec1.250SeniorNotesdue2031Member", "nsuri": "http://www.abbvie.com/20200501", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec1.375SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]", "label": "Sec 1.375 Senior Notes Due 2024 [Member]", "terseLabel": "Sec 1.375 Senior Notes Due 2024 [Member]" } } }, "localname": "Sec1.375SeniorNotesDue2024Member", "nsuri": "http://www.abbvie.com/20200501", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "abbv_Sec2.125SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sec 2.125 Senior Notes due 2028 [Member]", "label": "Sec 2.125 Senior Notes due 2028 [Member]", "terseLabel": "Sec 2.125 Senior Notes due 2028 [Member]" } } }, "localname": "Sec2.125SeniorNotesdue2028Member", "nsuri": "http://www.abbvie.com/20200501", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]", "terseLabel": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 17 0001551152-20-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551152-20-000010-xbrl.zip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end